Phase 1b study of AMG 757, a half-life extended bispecific T-cell engager (HLE BiTEimmune-oncology therapy) targeting DLL3, in de novo or treatment emergent neuroendocrine prostate cancer (NEPC).

被引：10

作者：

Aggarwal, Rahul Raj

Aparicio, Ana

Heidenreich, Axel

Sandhu, Shahneen Kaur

Zhang, Yiran

Salvati, Mark

Shetty, Aditya

Sadraei, Nooshin Hashemi

机构：

[1] Univ Calif San Francisco, San Francisco, CA USA

[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[3] RWTH Aachen, Univ Hosp, Aachen, Germany

[4] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[5] Amgen Inc, Thousand Oaks, CA 91320 USA

来源：

关键词：

D O I：

10.1200/JCO.2021.39.15_suppl.TPS5100

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS5100

引用

页数：3